Partnerships & Collaborations
Advancing Innovative Science Through Partnership
We are continually seeking opportunities with leading biopharmaceutical companies to identify areas of scientific synergy and address unmet medical needs. Through partnerships and collaboration, we can leverage Centyrins to target and deliver diverse therapeutic payloads, including oligonucleotides, proteins, small molecules, cell therapies, nanoparticles and other modalities to specific tissues of interest.
In January 2020, Aro announced a licensing and collaboration agreement with Ionis Pharmaceuticals, the leader in antisense oligonucelotides, focused on cell-specific delivery of antisense oligonucleotides. In October 2020, Ionis exercised its option to license the first ASO-Centyrin target pair for further development and commercialization. Additional collaborative research programs spanning several disease areas are ongoing.